B of A Securities Maintains Buy on Amicus Therapeutics, Lowers Price Target to $13
B of A Securities Maintains Buy on Amicus Therapeutics, Lowers Price Target to $13
Bof A證券維持對Amicus Therapeutics的買入，將目標股價下調至13美元
B of A Securities analyst Tazeen Ahmad maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and lowers the price target from $14 to $13.
B of A Securities分析師塔澤恩·艾哈邁德維持Amicus Therapeutics（納斯達克股票代碼：FOLD）的買入並將目標股價從14美元下調至13美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。